In the same way that benzos can make anxiety worse in the long term, can antidepressants worsen the condition they are designed to treat? Proud to have commissioned this thoughtful analysis: bit.ly/2GDRMgj@TAPsychopharm /1
Current diagnostic systems in psychiatry do not consider the iatrogenic components of psychopathology, and can be applied to only patients who are drug free. They are suited for a patient who no longer exists: most of the cases that are seen in psychiatric clinical practice.../2
"...receive psychotropic drugs and such treatment is likely to affect prognosis and treatment choices."/3
"Continued drug treatment with antidepressant medications may stimulate processes that run counter to the initial acute effects of a drug. The oppositional model of tolerance may explain loss of treatment efficacy during maintenance treatment and the fact that some side .../4
...effects tend to occur only after a certain time" /5
"When drug treatment ends, oppositional processes no longer encounter resistance, resulting in potential onset of new withdrawal symptoms, persistent post-withdrawal disorders, hypomania, and resistance to treatment if it is reinstituted" /6
"In all these cases, antidepressant medications may constitute a form of iatrogenic comorbidity, which increases chronicity and vulnerability to depressive episodes." /7
"Current prescription practices need to be reformulated in light of consideration of vulnerabilities and adverse effects of treatment." /8
"[use of ADs for relapse prevention]... is based mainly on clinical trials where remitted patients were randomized to drug continuation or placebo, without any differentiation between withdrawal and relapse."/9
"If we take into consideration the potential benefits, the likelihood of responsiveness, and the potential adverse events and vulnerabilities entailed by oppositional mechanisms, we would be inclined to target the application of AD only to the most severe and persistent..." /10
... cases of depression for the shortest possible time, and avoid their utilization in anxiety disorders" /11
• • •
Missing some Tweet in this thread? You can try to
force a refresh
How to taper antipsychotic medication to minimise withdrawal problems: more slowly than you think, down to fractions of usually used doses. Might need liquid versions, pill cutters. Thks Robin Murray, David Taylor @sameerjauhar Sridhar Natesan @JAMAPsychbit.ly/2XyvtxM
Summary: Antipsychotics can reduce psychotic symptoms and might reduce relapse rates so can be useful. But lots of side effects: tardive dyskinesia, metabolic problems, subjectively unpleasant, probable brain shrinkage. 1/
Doses should therefore be reduced to minimal effective dose, which for some might be zero. Also evidence that functioning (employment, independent living, relationships) improve for less or no antipsychotic /2
Ketamine, like other anaesthetic agents propofol and nitrous oxide, reduces depression scores in 2 hours. Does that make esketamine a safe and effective antidepressant? No. With @joannamoncrieff in @TheBJPsychbit.ly/3gw4cUC (thread)
We analysed studies submitted by Janssen to FDA to licence esketamine (esk) for treatment-resistant depression (TRD). TRD sounds rare and severe, but Janssen’s defn - people who have ‘failed’ two different ADs - likely to include many current AD users. (1/25)
Esk is one of two mirror image molecules that make up ket. Esk is 2xpotent as ket. 3 trials conducted for 4 weeks to compare esk to placebo. In 2 of these trials there was no sig. difference between esketamine and pbo. (2/25)